P06.02.B Advanced CAR-T cell against orthotopic glioblastoma mouse model

Abstract Background The adoptive and engineered chimeric antigen receptor (CAR) T cells have demonstrated remarkable success in treating hematologic cancers; however, this has yet to be extrapolated solid tumors such as glioblastoma multiforme (GBM). purpose of study was evaluate the survival efficacy using advanced CAR-T orthotopic GBM mouse model. Material Methods Advanced cell, which reprograms patient’s T-cells with a transgene encoding part interleukin-7 receptor-α (ΔIL7Rα) domain addition CD3ζ signaling 4-1BB costimulatory CAR gene exhibit excellent vivo persistence anti-tumor effect cells. In gene, TGF-beta converter is introduced, converts inhibitory signal TGF-beta, an immunosuppressive cytokine overexpressed hostile tumor microenvironment, into activation IL-18 cells.DAY9 NSG mice bearing orthotopically xenografted cell lines (1 × 105 U251MG expressing IL13Rα2) were randomized 8 experimental groups. Each group intravenously injected only once different subtype (Td ~ 47.3% 5 106) monitored for survival. Results Among treatment groups, treated TGF-β statistically significant increase (p=0.042, 95%CI, 0.375-0.981) compared other subtypes. DAY9 model, we showed that single I.V. injection targeting IL13Rα2-specific achieved benefit. Conclusion This first report show benefit model cells, merits further clinical trials real world setting.